
Can KISQALI help reduce the risk of recurrence?
In the NATALEE trial, KISQALI® (ribociclib), in combination with an aromatase inhibitor (AI), improved invasive disease-free survival (iDFS), helping to reduce the risk of recurrence vs AI alone in the broadest range of patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence; iDFS at 3 years was 90.7% for KISQALI + AI vs 87.6% for AI alone (absolute difference 3.1%; median follow-up of 33.3 months; HR=0.749 [95% CI: 0.628-0.892]). Explore the risk reduction data below.1-3
In patients with stage II/III HR+/HER2- eBC,
Over 5 years, KISQALI delivered a 28% reduction in the risk of recurrence vs AI alone
The iDFS benefit deepened over time with KISQALI + AI, beyond the 3-year treatment period
In the 3-year final analysis (median follow-up of 33.3 months)1,2:
iDFS at 3 years was 90.7% for KISQALI + AI vs 87.6% for AI alone (absolute difference 3.1%)
There was a 25.1% relative reduction in the risk of an iDFS event; HR=0.749 (95% CI: 0.628-0.892)
In an interim analysis, at a median follow-up of 28 months, a statistically significant reduction in risk was achieved despite the greater challenge of showing clinical benefit in a broad range of patients.1,3,4
NATALEE: KISQALI + AI vs AI alone at 5 years (median follow-up of 55.4 months)
Hazard ratio is based on stratified Cox model.6
iDFS was defined as the time from randomization to the date of the first event of local invasive breast cancer recurrence, regional invasive recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer (excluding basal and squamous cell carcinomas of the skin), or death (any cause).1
In the 5-year prespecified analysis5:
At 3 years: 2.7% absolute difference in iDFS*
At 5 years: 4.5% absolute difference in iDFS
At the time of data cutoff, only 12.4% of patients receiving KISQALI + AI had experienced an iDFS event vs 15.9% of patients treated with AI alone
The 5-year analysis was prespecified and descriptive in nature; as such, there was no prespecified statistical procedure controlling for type 1 error
*The difference between percentages does not equal 2.7 due to rounding.5
KISQALI can help reduce the risk of recurrence, including distant recurrence with incurable metastatic disease |
NATALEE was a randomized, multicenter, open-label, phase III study of KISQALI + letrozole or anastrozole (n=2549) vs letrozole or anastrozole (n=2552) for the adjuvant treatment of men and women with stage II/III HR+/HER2- eBC, including all those with node-positive or high-risk node-negative disease (eligible stages and nodal status include: anatomic stage group IIB-III, or anatomic stage group IIA that is either node positive, or node negative with histologic grade 3, or histologic grade 2 with Ki-67 ≥20% and/or high risk by gene signature testing). iDFS was the primary end point.1,2
AI, aromatase inhibitor; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR, hazard ratio; HR+, hormone receptor-positive; iDFS, invasive disease-free survival.
KISQALI + AI iDFS data across subgroups, including stage, nodal status, or menopausal status
KISQALI may be right for a variety of patients with stage II/III HR+/HER2- eBC.

Explore the KISQALI patient profiles
Identify eligible patients like Jasmine, Erin, and Katrice today

